📇 Rhumatologue · CLICHY · (92) · Hospitalier

MME Carla ISSA-HONEIN

Pourquoi vous devez consulter ce praticien

4 raisons identifiées

Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
24 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
14 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
136 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 CLICHY (92)HospitalierRPPS 10100053056

✨ Génération du profil synthétique IA en cours…

Lieux de consultation(14)

SANTE MEDECINE SERVICE SMS
9 RUE VILLENEUVE, 92110 CLICHY
Activité de soin et de pharmacie
SANTE MEDECINE SERVICE SMS
5 RUE DE LA CLAIRIERE, 91000 EVRY
Activité de soin et de pharmacie
SANTE MEDECINE SERVICE SMS
HOPITAL PRIVE DU VAL D'YERRES 31 AVENUE DE L ABBAYE AVENUE DE L ABBAYE, 91330 YERRES

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Longitudinal Progression of Myopic Maculopathy in a Long-Term Follow-Up of a European Cohort: Imaging Features and Visual Outcomes

Ophthalmology. Retina · 2025

📚 7 citations🎯 RCR 3.46🩺 Clinique🔓 Open Access

The Paul Glaucoma Implant: a systematic review of safety, efficacy, and emerging applications

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025

📚 6 citations🎯 RCR 3.17🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Purpose The Paul Glaucoma Implant (PGI) is a novel non-valved glaucoma drainage device designed to lower intraocular pressure (IOP) in patients with refractory glaucoma. This systematic review aims to evaluate the current evidence on safety, efficacy, and emerging applications of PGI implantation. Methods A systematic literature search was conducted following PRISMA guidelines across PubMed/Medline, Embase, Cochrane, Google Scholar, and Web of Science databases up to April 2025. Quality assessment was performed using the NIH Quality Assessment Tool for Before-After Studies. Data on patient demographics, surgical techniques, IOP outcomes, success rates, and complications were extracted and analyzed. Results Eighteen studies (946 eyes) met the inclusion criteria. The PGI consistently demonstrated significant IOP reduction across various studies and glaucoma subtypes. Mean IOP reductions ranged from 14.8 mmHg to 19.1 mmHg, depending on follow-up duration and patient characteristics. Complete success rates ranged from 38.4% to 75%, while qualified success rates were consistently high, reaching up to 93.2%. The PGI's unique design, featuring a smaller inner tube diameter (0.127 mm), is thought to contribute to a lower risk of hypotony compared to other non-valved implants. Three comparative studies with other GDDs reported similar success rates with potentially fewer early complications. Quality assessment revealed moderate-to-good quality evidence, with limitations including short follow-up periods and predominance of uncontrolled studies. Conclusions The PGI is emerging as a safe and effective surgical option for treating refractory glaucoma. Its smaller tube diameter and large surface area endplate contribute to efficient IOP control with a potentially lower risk of hypotony.

Drug-Coated Balloons Versus Non-Coated Balloons for Side Branch Treatment in Bifurcation Lesions: A Systematic Review and Meta-Analysis

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025

📚 3 citations🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

ABSTRACT Background Coronary bifurcation lesions (CBL) account for ~20% of percutaneous coronary interventions (PCI). When using provisional stenting, optimal management of a diseased side branch (SB) remains debated. Drug‐coated balloons (DCBs) are an emerging option, but data on their role in CBL PCI are limited. Aims We conducted a meta‐analysis to compare DCBs and non‐compliant balloons (NCBs) for SB treatment. Methods A systematic search of MEDLINE, CENTRAL, and EmBase (until November 2024) identified studies comparing DCBs and NCBs for treating the SB. From 1451 studies, five were included (two randomized controlled trials [RCTs], three observational), with 1762 patients, predominantly male with acute coronary syndrome (ACS). The primary outcome was major adverse cardiac events (MACE); secondary outcomes included myocardial infarction (MI), target lesion revascularization (TLR), and target vessel revascularization (TVR). Results DCBs significantly reduced MACE (pooled OR 0.48, 95% CI 0.34–0.68, p < 0.0001, I ² = 0%) and MI (pooled OR 0.39, 95% CI 0.25–0.62, p < 0.001, I ² = 0%) compared to NCBs. No significant differences were observed in TLR or TVR. Subgroup analysis confirmed consistency across observational studies and RCTs for MACE and MI. Conclusions DCBs in SB treatment during CBL PCI are associated with reduced MACE and MI compared to NCBs, with no significant differences in vessel‐specific outcomes. These findings suggest a potential clinical benefit of DCBs in reducing ischemic events, while limiting stenting in CBL. Further research is needed to refine patient selection and optimize outcomes.

Cookies & analyse de trafic

MME Carla ISSA-HONEIN

Pourquoi vous devez consulter ce praticien

Lieux de consultation(14)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (24) — classées par pathologie

Transversal11

Revue générale7

Case report / série3

Revue / méta-analyse3

Épidémiologie & registres1

Lupus1

Microbiote1

Pharmacovigilance1

SAPL1

Vascularites des gros vaisseaux1

Vraie vie / RWE1

Partager cette fiche